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doi: 10.1016/j.exphObjective. Polo-like kinase 1 (Plk1) is a regulator of the cell cycle that has been implicated in
the pathology of many cancers. We have investigated whether this kinase plays a role in
multiple myeloma (MM) using the Plk1 inhibitor BI 2536.
Materials and Methods. We have used six MM cell lines and six patient-derived samples to
determine the effects of the Plk1 inhibitor, BI 2536, on cell viability, apoptosis, and cytoki-
nesis. We have also examined the effect of the microenvironment on these parameters and
the effects of BI 2536 in combination with other antimyeloma agents.
Results. We show that MM cell lines and patient samples express PLK1 and that cell death by
apoptosis occurs when Plk1 is inhibited. Cells treated with BI 2536 accumulate in the G2/M
phase of the cell cycle causing endoduplication. The effects of BI 2536 are not abrogated
when cells are cultured on extracellular matrix components, in the presence of interleukin-
6, or with bone marrow stromal cells.
Conclusions. Plk1 inhibition leads to cell death in MM cell lines and patient myeloma samples.
Our data suggest that inhibition of Plk1 may have potential use as a therapeutic strategy in
multiple myeloma.  2011 ISEH - Society for Hematology and Stem Cells. Published by
Elsevier Inc.Polo-like kinase 1 (Plk1) is one of four polo-like kinase
proteins with different subcellular locations and functions
involved in cell-cycle regulation, particularly during G2
and mitosis, and it also plays an important role in inhibiting
apoptosis [1]. The polo-like kinases belong to a family of
mitotic serine/threonine kinases, which contain one or
two C-terminal regions, known as polo box domains, and
a highly conserved N-terminal kinase domain. Plk1 is
highly expressed in malignant cells and serves as a negative
prognostic marker in many human cancer types, including
hematological cancers [2,3]. Forced expression of Plk1
results in multinucleation, which is a feature of many
cancer cells and characteristic of chromosomal instability.
The role of polo-like kinases in multiple myeloma (MM)
has yet to be addressed. MM is characterized by the malig-
nant growth of immunoglobulin-producing plasma cells,
mainly in the bone marrow. Despite the introduction ofishikova contributed equally to this work as first
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em.2010.12.006proteasome inhibitors and immunomodulatory agents in
the treatment of this condition, patients invariably relapse,
highlighting the need for developing alternative treatment
strategies. The observation that the proliferation rate of
MM cells tends to rise with progression of the disease
suggests that targeting the polo-like kinases may represent
an attractive therapeutic target.
This study shows that the Plk1 inhibitor BI 2536 [4]
effectively kills MM cells in a time- and dose-dependent
manner and that this effect is not influenced by components
of the extracellular matrix (ECM), interleukin-6 (IL-6), or
bone marrow stromal cells. Moreover, the action of BI
2536 is potentiated when combined with bortezomib and
dexamethasone, revealing synergy with these drugs. Our
results suggest that inhibition of Plk1 represents an attrac-
tive therapeutic strategy in the treatment of MM.Materials and methods
Materials
BI 2536 was obtained from Axon Medchem (Groningen, The
Netherlands). Bortezomib was obtained from LC Laboratories
(Boston, MA, USA). Dexamethasone, Histopaque 1077, ECM,ogy and Stem Cells. Published by Elsevier Inc.
331H.J. Stewart et al./ Experimental Hematology 2011;39:330–338laminin, and fibronectin were obtained from Sigma (Poole, UK).
Penicillin, streptomycin, L-glutamine, RPMI 1640, Trizol, and
reverse transcription polymerase chain reaction (PCR) primers
were purchased from Invitrogen (Paisley, UK). Fetal calf serum
was purchased from Biosera (Ringmer, UK). IL-6 was purchased
from Peprotech (London, UK). Celltiter-Glo kit and Caspase-Glo
8 kit were purchased from Promega (Southampton, UK). Taq
polymerase and human reference RNAwere purchased from Stra-
tagene. CD138 microbeads were purchased from Miltenyi Biotec
(Bisley, UK). WST-1 reagent was purchased from Roche (Burgess
Hill, UK). Annexin-V/propidium iodide kit was purchased from
BD Biosciences (Oxford, UK). Quantitech cDNA kit was
purchased from Qiagen (Crawley, UK).
Cell lines and primary samples
A total of six human MM cell lines were used in this work:
MM.1S, RPMI-8226, U-266, MM1R, KMS-12, and MOLP-8.
These cells were a kind gift from Dr. E. Ocio (University of
Salamanca), Drs. S. Sahota and B. Guinn (University of South-
ampton), and Dr. Y. Calle (King’s College Hospital, London).
The integrity of these cell lines was assessed by protein electro-
phoresis of cell supernatants to confirm production of the expected
type of monoclonal immunoglobulin. Enhanced green fluorescent
protein MM.1S cells and cherry redexpressing HS-5 stromal
cells were from Dr. Calle [5]. Untransfected HS-5 stromal cells
were from Dr. Ocio. Cells were cultured in RPMI-1640 (or
Dulbecco’s modified Eagle’s medium, in the case of HS-5 cells)
supplemented with 10% fetal calf serum, 100 mM L-glutamine,
penicillin (100 IU/mL), and streptomycin (100 mg/mL).
A total of six myeloma patient samples were studied. All
primary bone marrow aspirates were taken from routine diagnostic
specimens after informed consent of the patients. The project
received approval from the local ethics committee (The Brighton
Blood Disorder Study, references 09/025/CHE and 09/H1107/1)
and was conducted in accordance with the Declaration of Helsinki.
Mononuclear cells were isolated by Histopaque 1077 density
gradient purification [6]. CD138þ plasma cells were isolated
from the mononuclear cell preparations by positive selection using
CD138 magnetic microbeads, according to manufacturer’s instruc-
tions. Purity of the cells was checked by flow cytometry.
Reverse transcription PCR
Total RNAwas extracted from cell lines (5 106 cells) using Trizol
reagent according to manufacturer’s instructions. RNA (1 mg) was
reverse transcribed using a Quantitech cDNA kit. Human reference
RNA was used as a positive control. Primers for human PLK genes
were as follows [7]: PLK1 Forward 50-TGACGGCACTGAGTCC
TACC-30, Reverse 50-AGGCCTTGAGACGGTTGCTG-30; PLK2
Forward 50-TCGGCTCTACCTCCTTCAGT-30, Reverse 50-GTTCT
GGTTCCAACCAGTCC-30; PLK3 Forward 50-CCACTTTGAGG
ACGCTGACA-30, Reverse 50-CTGCTGATAGGGAGTCGATC-30;
PLK4 Forward 50-ACCACCCTCACCTACTGACA-30, Reverse 50-
GTGCCTGTGTTGGAGAAGCA-30; glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) Forward 50-AGGGGTCTACATGGCAA
CTG-30, Reverse: 50-CGACCACTTTGTCAAGCTCA-30. The PCR
cycles were as follows: PLK1 (35 cycles, 440 bp), PLK2 (30 cycles,
420 bp),PLK3 (35 cycles, 580 bp),PLK4 (35 cycles 600 bp), GAPDH
30 cycles, 228 bp. Each cycle consisted of denaturation (94C for 15
seconds), annealing (30 seconds), and extension (72C for 30
seconds). The annealing temperatures were as follows: 60C forPLK1, 57C for PLK2, 56C for PLK3, 55C for PLK4, 54C for
GAPDH. The first cycle was preceded by a denaturation step of 3
minutes at 94C and the last one was followed by an extension step
of 3 minutes at 72C. The resulting PCR fragments were PLK1
(440 bp), PLK2 (420 bp), PLK3 (600 bp), PLK4 (580 bp), GAPDH
(228 bp), and were run on 1.5% agarose gels containing Gel Red
and visualized under ultraviolet light.
Cell viability assays
For cell lines, cell viability was assessed using a WST-1 (4-
[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene
disulfonate) assay. The 5104 cells plated perwell in 96-well plates
were incubated in the presence of drug for the times indicated.
For patient samples, 1  104 cells were plated in 96-well plates
and cell viability measured using a luminescent Celltiter-Glo kit
according to manufacturer’s instructions. The viability of untreated
cells was set as 100% and viability in other groups was calculated
by comparing the optical density readings with the control. BI
2536 was dissolved in dimethyl sulfoxide and stored at 20C.
Dilutions in phosphate-buffered saline (PBS) were used for all
experiments.
Growth curves
MM cells were plated at a density of 5 104 cells per well in a 24-
well plate in 400 mL cell culture medium in the presence or absence
of 100 nMBI 2536. PBSwas added to control wells. Every 24 hours
for 72 hours, cells were counted in the presence of trypan blue (to
determine cell viability) and the results recorded.
Coculture experiments
HS-5 bone marrow stromal cells (cherry redexpressing) were
plated onto 13-mmglass coverslips and grown in RPMIþ 10% fetal
calf serum until confluent. Fifty thousand enhanced green fluores-
cent proteinMM.1S cells were seeded onto the HS-5 cells [5]
and cultured in the presence or absence of BI 2536 for 24 hours.
After this time, coverslips were fixed in 4% paraformaldehyde for
10 minutes and stained with 4,6-diamidino-2-phenylindole. After
a final wash through PBS, coverslips were mounted in Citifluor
anti-fade mounting medium and viewed for immunofluorescence
using a Leica DM 5000B microscope fitted with a Leica
DPC300FX digital camera. The number of green fluorescing
MM.1S cells was counted in images of five random fields taken at
5 magnification.
Cell adhesion to laminin, fibronectin, and ECM
Laminin and fibronectin (10 mg/mL) were applied to a poly-L-
lysinecoated 96-well plate for 1 hour at room temperature.
The substrates were aspirated and immediately replaced with
medium containing the indicated number of cells. ECM solution
was obtained by dissolving ECM in ice-cold PBS. The ice-cold
ECM solution (50 mL) was then pipetted into the wells of
96-well tissue culture plates. Gelling of the ECM coating of the
well was achieved by incubation at 37C, as described previously
[6]. Cells were plated directly onto the gelled ECM.
Apoptosis assays
BI 2536induced apoptosis of MM cell lines and a patient sample
were assayed using an Annexin-V/propidium iodide kit according
to manufacturer’s instructions. Analysis of Annexin-V/propidium
iodide staining by flow cytometry was carried out using a Becton
Dickinson LSR II with data acquisition software FACS Diva.
332 H.J. Stewart et al./ Experimental Hematology 2011;39:330–338Activation of caspase-8 was measured using a Caspase-Glo 8
assay (Promega). Cells were plated in black 96-well plates at
a density of 10,000 cells per well and treated with 100 nM BI
2536 for 24 hours.
Immunolabeling
MM cell lines were plated onto poly-L-lysinecoated coverslips
for 24 hours, then treated with 100 nM BI 2536 for an additional
48 hours. After this time, coverslips were fixed in 4% paraformal-
dehyde for 10 minutes, rinsed through PBS, then incubated in
fluorescein isothiocyanateconjugated rabbit antiAnnexin-V
together with propidium iodide for 30 minutes at room tempera-
ture. After a final wash through PBS, coverslips were mounted
in Citifluor anti-fade mounting medium and viewed for immuno-
fluorescence using a Leica DM 5000B microscope fitted with
a Leica DPC300FX digital camera.
Statistical analysis
All values are shown asmean6 standard error of mean from at least
three independent experiments (or a representative experiment of
three is shown) and considered significant if p! 0.05. Significance
between groups was calculated using Student’s t-tests.Figure 1. Multiple myeloma cell lines express and patient samples express
PLK genes. Reverse transcription PCR was carried out on complementary
DNA prepared from 1 mg RNA from three cell lines and five patient
samples. (A) Lane 1: MM.1S, Lane 2: RPMI-8226, Lane 3: U-266. (B)
Patient samples.Results
PLK genes are present in MM cells
We initially carried out experiments to determine which
of the PLK messenger RNAs were detectable in MM cells.
U-266, MM.1S, and RPMI-8226 were used for this purpose.
The results confirm that these cell lines express all four PLK
genes (Fig. 1A). Because inhibitors of Plk1 are readily avail-
able and Plk1 expression is associated with malignant
progression, we chose to continue our study focusing on
this enzyme.
Expression of PLK1 was assessed in five primary
myeloma cell samples by reverse transcription PCR using
RNA extracted from bone marrow plasma cells. PLK1
expression was detected in all samples, suggesting that
Plk1 is a legitimate therapeutic target in myeloma
(Fig. 1B). By contrast, we did not detect PLK1 expression
in normal bonemarrow cells consistent with available micro-
array results (UCSC genome bioinformatics Website) ob-
tained using GNF gene expression atlas 2 data from U133A
and GNF1H chips.
BI 2536 induces cytotoxicity in MM cell lines and
patient samples in a dose- and time-dependent manner
In order to determine the effect of inhibition of Plk1 on
myeloma cells, we treated MM cell lines (Fig. 2A) and
CD138þ plasma cells from patient samples (Fig. 2B) with
varying doses of BI 2536 (0.001–100 mM), a potent and
highly specific inhibitor of Plk1, for a 48-hour period.
Cell viability was assessed using WST-1 or a luciferase-
based assay (Celltiter-Glo). IC50 values for the MM cell
lines RPMI-8226 and MM.1S were #10 nM, which were
significantly lower than the IC50 values from nonmalignanttissues. The U-266 cell line had a higher IC50 value of 1 to
10 mM, which was similar to the IC50 value of CD138
þ
plasma cells from newly diagnosed MM patients, also 1
to 10 mM. Peripheral blood mononuclear cells (data not
shown) and confluent cultures of HS-5 cells (Fig. 2C) had
IC50 values of w100 mM.
Examination of the effect of 100 nM BI 2536 on MM
cell lines during a 72-hour period showed that nearly all cells
had died/arrested during this time (Fig. 2D). Cell death/arrest
is induced in around 50% of cells from all cell lines by 48
hours. To establish that inhibition of cell growth was occur-
ring, we carried out growth curves in the presence of 100 nM
BI 2536 using MM cell lines. Growth curves of MM cell
lines show that in the presence of BI 2536 cell growth is in-
hibited (Fig. 2E and F).
BI 2536 induces MM cell cytotoxicity in the presence of
ECM components, IL-6, and bone marrow stromal cells
As the activity of MM cells is known to be regulated by the
bone marrow microenvironment [8,9], we sought to deter-
mine the effect of this environment on the response of
MM cells to BI 2536. We used ECM, laminin, and fibro-
nectin as cell culture substrates. Treatment of MM cells
Figure 2. The Plk inhibitor BI 2536 inhibits MM cell viability in a dose-dependent manner. Cell lines (A) and patient samples (B) were treated with various
doses of BI 2536 for 48 hours and cell viability assessed. Confluent HS-5 cells are less responsive to BI 2536 (C). A time-response curve to 100 nM BI 2536
is shown (D). Growth curves for MM cells during a 5-day period (E, F). Data are representative of at least three independent experiments performed in triplicate.
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cells from cell death (Fig. 3A). Furthermore, the in vitro
activity of BI 2536 was not suppressed by IL-6, a potent
MM cell survival factor, or in the presence of ECM togetherwith IL-6 (Fig. 3B). In additional experiments, we cultured
MM.1S cells expressing green fluorescent protein on mono-
layers of HS-5 bone marrow stromal cells. Treatment of
these cells with 100 nM BI 2536 did not protect the cells
334 H.J. Stewart et al./ Experimental Hematology 2011;39:330–338from cell death, showing that BI 2536 is active even in the
presence of stromal cells.
BI 2536 induces apoptosis and endoduplication
in MM cells
In order to determine whether the decrease in cell viability
seen in MM cells treated with BI 2536 was due to
apoptosis, we assessed the presence of apoptotic cells by
measuring Annexin-V staining and propidium iodide
uptake in MM cells by flow cytometry. Results showed
BI 2536 caused a dose-dependent induction of apoptosisFigure 3. BI 2536 can overcome the protective effects of the bone marrow micr
laminin (LN), fibronectin (FN), extracellular matrix (ECM), or tissue culture pla
cultured on TCP in the presence of 10 ng/mL IL-6, 100 nM BI 2536, or IL6 þ
ng/mL IL-6, 100 nM BI 2536, or IL-6 þ BI 2536. (D) Enhanced green fluo
bone marrow stromal cells in the presence or absence of BI 2536 for 24 hours. (E
experiment on the RPMI-8226 cell line.in both cell lines (Fig. 4A) and a patient sample (not shown)
within 24 hours. These results were confirmed by immuno-
labeling cells cultured in the presence of 100 nM BI 2536
with antiAnnexin-V (Fig. 4B). To confirm that BI 2536
was preventing cytokinesis in MM cell lines, we permeabi-
lized the cells and labeled with propidium iodide. Flow
cytometry revealed that BI 2536 results in an increased
proportion of 4N cells and also a population of 8N cells
indicative of endoreduplication (Fig. 4C). This occurs
when G2/M cells fail to separate after DNA synthesis and
proceed to a further cycle. Analysis of the mechanism ofoenvironment. (A) MM cell lines (50,000 cells per well) were cultured on
stic (TCP) in the presence or absence of 100 nM BI 2536. (B) MM cells
100 nM BI 2536. (C) MM cells cultured on ECM in the presence of 10
rescent protein expressing MM.1S cells cultured on mCherry-expressing
) Photomicrographs of cell cultures. Data shown are from a representative
335H.J. Stewart et al./ Experimental Hematology 2011;39:330–338apoptosis in these cells revealed that caspase-8 activation
had occurred (Fig. 4D).
BI 2536 shows synergy with bortezomib and
dexamethasone
Bortezomib and dexamethasone are routinely used in treat-
ment of MM. Therefore, it was of interest to determine
whether inhibition of Plk1 would potentiate antimyeloma
activity of these drugs. We combined doses of drugs that
caused !50% inhibition of cell viability when used alone.Figure 4. BI 2536 causes apoptosis, endoduplication, and caspase-8 activation in
for 24 hours then analyzed for Annexin-V and propidium iodide expression by fl
immunolabeled using fluorescein isothiocyanatelinked antiAnnexin-V and sta
microscope fitted with a Leica DPC300FX digital camera using a 40 objective.
mm. (C) MM.1S cells were analyzed by propidium iodide (PI) cell-cycle analysis
of 8N cells indicative of endoreduplication by 24 hours. (D) CD138þ patient ce
assayed for caspase-8 activation.Our results showed that when MM cell lines (RPMI-8226,
U266 and MM.1S) were treated with BI 2536 combined
with either bortezomib or dexamethasone, there was poten-
tiation of cell killing indicative of drug synergy (Fig. 5).Discussion
This study shows that all four polo-like kinase genes are ex-
pressed in MM cell lines and that inhibition of one of these,
Plk1, results in MM cell death by apoptosis. Plk1 was alsoMM cells. (A) MM.1S cells were treated with 10 nM and 100 nM BI 2536
ow cytometry. (B) Cells were plated in 100 nM BI 2536 for 48 hours then
ined with propidium iodide. Photos were taken using a Leica DM 5000B
Images were captured using Leica application suite software. Scale bar: 10
. This reveals an increased proportion of 4N cells in G2/M and a population
lls were plated at a density of 10,000 cells per well in 96-well plates and
336 H.J. Stewart et al./ Experimental Hematology 2011;39:330–338found to be present in patient samples. Plk1 is the only
isoform shown to be involved in the activation of Cdk1,
chromosome segregation, centrosome maturation, bipolar
spindle formation, and execution of cytokinesis [1]. Plk1
activity is elevated in tissues and cells with a high mitotic
index and Plk1 is often overexpressed in tumors, suggesting
that it may be a highly suitable target for cancer therapy
[10]. About 80% of human tumors of various origins
express high levels of Plk1 transcripts. However, Plk1
messenger RNA is mostly absent in surrounding healthy
tissues [11]. Plk2 and Plk3 regulate G1 and early S phase
entry [12,13], while Plk3 is downregulated in some cancers
[14]. Plk4 functions in centriole duplication [15].
In this study, we show that the Plk1 inhibitor BI 2536
induces cell death by apoptosis in both cell lines and patient
samples. BI 2536 treatment results in accumulation of 4N
cells arrested at G2/M and a population of 8N cells indica-
tive of endoduplication. Interestingly, the sensitivity of
primary patient samples prepared from bone marrow aspi-
rates is lower than that observed for cell lines (110 mM
for primary MM cells vs. 110 nM for most cell lines).
We speculate that this is attributable to a lower mitotic
rate in primary MM cells and also the U266 cell line that
had a higher than expected IC50 level. We predict that cells
from relapsed MM patients, which have shorter tumor-
doubling times, would exhibit greater drug sensitivity [16].
The IC50 level for the primary MM cells was in the range
of 1 to 10 mM. In phase I, dose-escalation and pharmacoki-
netic studies of BI 2536 in patients with advanced solid
tumors, the maximum tolerated dose was 200 mg, which
would produce an estimated tissue concentration of approx-
imately 10 mM (consistent with the measured plasma
concentrations of 110 mM) [17]. BI 2536 is currently inFigure 5. BI2526 enhances the action of bortezomib or dexamethasone. MM.1
treated with 1 nM BI 2536 alone or in combination with 15 nM dexamethaso
a WST-1 assay.phase II/III clinical studies, although this is not the only
Plk1 inhibitor under development. Several others, such as
BI 6727, are in phase I trials with other inhibitors in
preclinical development [18].
Interestingly, we observed that cell viability, as measured
by proliferation growth curves, was blocked at lower concen-
trations of BI 2536, for instance, 100 nM vs. 10 mM for the
cell line U266. This indicates that cell-cycle arrest occurs at
lower concentrations than required for inducing apoptosis.
Thus, BI 2536 is cytostatic at low doses and cytotoxic at
high doses, suggesting that it might be well suited to syner-
gistic activitywhen combinedwith other antimyeloma agents.
In healthy tissues where cell division is minimal, such as
peripheral blood mononuclear cells and confluent cultures
of the stromal cell line HS-5, there is a limited reduction in
cell viability at doses of BI 2536 that are highly toxic to
MM cells. Cell death proceeds by activation of caspase-8,
suggesting that the extrinsic pathway of apoptosis is involved
in death of MM cells [19]. Importantly, we observed
enhanced toxicity when BI 2536 was combined with either
bortezomib or dexamethasone, suggesting synergy between
these different classes of drugs.
One of the particular difficulties regarding treatment
of MM is overcoming the influence of the bone marrow
microenvironment, which is recognized as being of great
importance in the pathology ofmyeloma through niche influ-
ences [9,20,21]. In these studies, we show that BI 2536 is able
to overcome the protective effects of this microenvironment.
The inhibitory effect of BI 2536 is not abrogated when cells
are cultured onmatrixmolecules, laminin, fibronectin, ECM,
or, indeed, on bone marrow stromal cells. Thus, BI 2536 can
overcome cell-adhesionmediated drug resistance of MM
cells. Furthermore, this drug was able to induce cell deathS were plated at a density of 50,000 cells per well in 96-well plates then
ne or 0.5 pM bortezomib for 48 hours. Cell viability was assessed using
337H.J. Stewart et al./ Experimental Hematology 2011;39:330–338in the presence of the potentmyeloma cell growth factor, IL-6
[22], and when IL-6 and ECM where used in combination.
The combination of ECM with IL-6 represents an environ-
ment more akin to that encountered by MM cells in vivo
than either factor alone. The observation that cell death
induced by BI 2536 occurs even when cells are cultured on
bone marrow stromal cells also supports these conclusions.
These effects are comparable to those seen for the aurora
kinase inhibitor VE-465 on MM cells, which is similarly
able to overcome the protective effects of both IL-6 and
stromal cell adherence [23], although in this study the effects
of cell-mediated drug resistance in combination with cyto-
kine effects were not tested.
Interestingly, there is some overlap in the mechanisms of
action of these two classes of drugs as aurora kinases are
also involved in cell division and Plk1 is activated by aurora
A [24]. However, both kinases have different effects on the
mitotic process [18]. Numerous inhibitors have been devel-
oped against both classes of kinases and some aurora kinase
inhibitors have been shown to have effects on multiple
myeloma [25–31]. Indeed, ENMD-2076 is currently under-
going phase I trial [18]. Whether Plk1 inhibitors or aurora
kinase inhibitors will ultimately prove most useful in the
treatment of MM will depend on the efficacy with which
they kill tumor cells and the levels of patient tolerance to
the drug [32].
In summary, inhibition of Plk1 may have potential use as
a therapeutic strategy in MM, either used alone or in combi-
nation with other antimyeloma therapies. Our data support
translational clinical studies of BI 2536 in myeloma
patients, particularly those with relapsed disease.Acknowledgments
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